A vs AIZ Stock Comparison

Scores Breakdown

Metric	A	AIZ
📈 Growth	26/30	26/30
💰 Profitability	17/20	14/20
🏦 Financial Health	15/20	15/20
💵 Valuation	16/20	12/20
⚠️ Risk (lower is better)	5/10	3/10
Overall Score	79/100	74/100

Side-by-Side Summaries

A Analysis	AIZ Analysis
📈 Growth & Financial Trajectory Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility. 💰 Margins & Cash Flow Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity. 🛡️ Balance Sheet & Liquidity Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure. ⚠️ Key Drivers & Risks Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption. Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.	📈 Growth & Financial Trajectory Over the 8 quarters, Revenues rose from about $2.967B in 2024 Q3 to $3.454B in 2026 Q2, roughly a 16% gain. Net Income advanced from about $133.8M to $298.6M, more than doubling, signaling improving operating leverage though occasional quarterly pauses (notably late 2025). The trend is broadly upward, supported by positive cash flow and expanding profits. 💰 Margins & Cash Flow Gross margin has hovered in the mid-to-high single digits to low double digits, averaging around 8–11%, with margin expansion by 2026. Operating margin followed suit, with 2026 Q2 showing about 11% OPM on revenue of $3.45B. Cash flow remains robust: Net cash from operating activities was strong in multiple quarters (e.g., 2026 Q2 ≈ $454.4M; 2026 Q1 ≈ $240.3M), while investing cash flow was negative as growth initiatives continued. Net cash flow overall was positive in several quarters. 🛡️ Balance Sheet & Liquidity Total assets (~~$36B) exceed liabilities (~~$30B), and equity sits around $6B, yielding a comfortable balance sheet. Current assets cover current liabilities, and there is minimal noncurrent debt, with steady operating cash flow underpinning liquidity. ⚠️ Key Drivers & Risks Drivers: Steady premium revenue growth; improving operating leverage. Risks: Catastrophe/claims volatility and regulatory/interest-rate sensitivity; competitive pricing pressure.

A Analysis

AIZ Analysis

📈 Growth & Financial Trajectory

Eight quarters show revenue rising from about $1.66B in 2024-Q1 to about $1.84B in 2026-Q2, while Net Income fluctuates but trends higher, with a peak near $434M in 2025-Q4 and a pace around $300–$339M in other quarters. The trend depicts steady top-line growth and durable earnings power despite quarterly volatility.

💰 Margins & Cash Flow

Gross Margin remains in the low-to-mid 50s% (roughly 53%), and Operating Margin sits in the low- to mid-20s% (roughly 21%). Cash flow remains broadly positive; Net Cash Flow From Operating Activities ranges in the hundreds of millions per quarter, while investing and financing activities swing, producing occasional negative free cash flow but overall liquidity.

🛡️ Balance Sheet & Liquidity

Assets run around $12.8–$13.0B, with long-term debt near $3.0B and equity attributable to parent around $6.1–7.0B. Current assets ($4.2–4.9B) cover current liabilities ($1.9–2.3B), indicating solid liquidity and resilience, despite occasional negative equity readings due to accounting structure.

⚠️ Key Drivers & Risks

Drivers: Life sciences instrumentation demand; continued R&D activity driving consumables and systems adoption.
Risks: Cyclicality of lab spending; valuation sensitivity and dependence on continued margin stability.

📈 Growth & Financial Trajectory

Over the 8 quarters, Revenues rose from about $2.967B in 2024 Q3 to $3.454B in 2026 Q2, roughly a 16% gain. Net Income advanced from about $133.8M to $298.6M, more than doubling, signaling improving operating leverage though occasional quarterly pauses (notably late 2025). The trend is broadly upward, supported by positive cash flow and expanding profits.

💰 Margins & Cash Flow

Gross margin has hovered in the mid-to-high single digits to low double digits, averaging around 8–11%, with margin expansion by 2026. Operating margin followed suit, with 2026 Q2 showing about 11% OPM on revenue of $3.45B. Cash flow remains robust: Net cash from operating activities was strong in multiple quarters (e.g., 2026 Q2 ≈ $454.4M; 2026 Q1 ≈ $240.3M), while investing cash flow was negative as growth initiatives continued. Net cash flow overall was positive in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets (~~$36B) exceed liabilities (~~$30B), and equity sits around $6B, yielding a comfortable balance sheet. Current assets cover current liabilities, and there is minimal noncurrent debt, with steady operating cash flow underpinning liquidity.

⚠️ Key Drivers & Risks

Drivers: Steady premium revenue growth; improving operating leverage.
Risks: Catastrophe/claims volatility and regulatory/interest-rate sensitivity; competitive pricing pressure.

Similar Companies

AMAT Score: 79 AME Score: 78 ANET Score: 85 GOOGL Score: 80 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"